Here are the latest stories being discussed in biopharma today:

1. Biotech firm Prime Medicine has obtained FDA authorization to begin its initial clinical trial for prime editing, pioneering a new chapter in advanced gene editing.

2. Deciphera Pharmaceuticals is set to become a subsidiary of Ono Pharmaceutical following a $2.4 billion buyout deal, spurred by the smaller company’s recent triumph in Phase 3 trials.

3. Amidst allegations of intellectual property transfer to Chinese officials, WuXi Biologics is striving to restore faith amongst its clientele. The company is aiming for increased transparency in operations to dispel concerns.

4. 4P-Pharma recently secured €15 million in investment, while Oncotelic Therapeutics has successfully sold rights to its range of cancer assets – a notable move in their ongoing business strategy.

5. Bristol Myers is making a big pivot by buying into Repertoire Immune Medicines, injecting new vitality into the Flagship-originated startup. This strategic collaboration focuses on developing vaccines for autoimmune diseases.

6. A two-decade-long collaboration between Johnson & Johnson and Addex Therapeutics suffered a setback as their leading drug candidate in epilepsy research failed to deliver promising results in Phase 2 trials.

7. The FDA has given its approval for X4 Pharmaceuticals’ new pill designed to treat the ultra-rare WHIM syndrome, a type of immunodeficiency disease. The treatment’s pricing will range from $372,300 to $496,400 per annum, depending on the patient’s weight.

8. Pharmaceutical leaders AstraZeneca and Daiichi Sankyo are celebrating another Phase 3 victory. This time it’s for their drug Enhertu, which is showing promising results in patients with HER2-low breast cancer.

In other news, Bristol Myers is looking to cut jobs and costs as it plans to close its Bay Area cell therapy R&D facility.